Compare AbbVie Inc (ABBV) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Xpeng Inc - ADR — how do they compare? AbbVie Inc trades at $249.7 (market cap $441.94B), while Xpeng Inc - ADR trades at $11.77 (market cap $11.15B). The key difference: AbbVie Inc is far larger — about 39.6× Xpeng Inc - ADR's market cap, and AbbVie Inc pays a 2.77% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| ABBV | XPEV | |
|---|---|---|
Market Cap | $441.94B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $28.07 |
52-Week Low | $197.38 | $11.68 |
Enterprise Value | $506.19B | $13.28B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
XPeng (XPEV) trades at $12.00, down 1.07% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $76.72 billion but a net loss of $1.14 billion, though the net margin improved to -1.49% from -14.17% in 2024. Recent news highlights vehicle delivery growth, international expansion, and advancements in autonomous driving technology.
The outlook is mixed: strong revenue growth and analyst buy ratings (64.7% consensus) suggest upside to the $17.00 price target, but persistent losses, high EV/EBITDA of 40.09, and competitive pressures pose risks. Investor sentiment is cautious amid earnings volatility and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
